All In MedTech

FDA Clearance Tracker · P000029-S075

DEFLUX INJECTABLE GEL

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 17, 2013 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 17, 2013

Approved

Time to decision

90 days

Received Jul 19, 2013. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P000029-S075
Device name
DEFLUX INJECTABLE GEL
Applicant location
Santa Barbara, CA
Received
Jul 19, 2013
Decided
Oct 17, 2013
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P000029

Device type

Device class
Class III

Every decision under product code LNM

FDA's approval statement

As written in FDA's record.

APPROVAL FOR LABELING CHANGES, WHICH ADD TWO ADDITIONAL TECHNIQUES FOR INJECTION, THE HIT AND DOUBLE-HIT.

Source documents

Other decisions for Palette Life Sciences

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.